Responsiveness to i.v. immunoglobulin therapy in patients with
toxic epidermal necrolysis: A novel pharmaco-immunogenetic
concept

J 2020

Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept

BOŘILOVÁ LINHARTOVÁ, Petra, Daniela GACHOVÁ a Břetislav LIPOVÝ

Základní údaje

Originální název

Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept

Autoři

BOŘILOVÁ LINHARTOVÁ, Petra (203 Česká republika, domácí), Daniela GACHOVÁ (203 Česká republika, domácí) a Břetislav LIPOVÝ (203 Česká republika, garant, domácí)

Vydání

JOURNAL OF DERMATOLOGY, HOBOKEN, WILEY, 2020, 0385-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30216 Dermatology and venereal diseases

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.005

Kód RIV

RIV/00216224:14110/20:00116596

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/1346-8138.15583

UT WoS

000571617900001

Klíčová slova anglicky

Fas receptor; gene variability; i; v; immunoglobulin therapy; pharmaco-immunogenetics; toxic epidermal necrolysis

Štítky

14110130, 14110229, 14110323, 14110518, podil, rivok, ÚMF

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 2. 2022 10:07, Mgr. Tereza Miškechová

Anotace

V originále

Toxic epidermal necrolysis (TEN) represents a rare drug-induced autoimmune reaction with delayed-type hypersensitivity that initiates the process of developing massive keratinocyte apoptosis, dominantly in the dermoepidermal junction. Although the etiopathophysiology has not yet been fully elucidated, the binding of Fas ligand (FasL, CD95L) to the Fas receptor (CD95) was shown to play a key role in the induction of apoptosis in this syndrome. The knowledge of the role of immunoglobulin G (IgG) in inhibition of Fas-mediated apoptosis contributed to the introduction of i.v. Ig (IVIg) in the therapy of TEN patients. Despite great enthusiasm for this therapy at the end of the 1990s, subsequent studies in various populations and meta-analyses could not unequivocally confirm the efficacy of the IVIg-based treatment concept. Today, therefore, we are faced with the dilemmas of how to adjust therapy of TEN patients most effectively, which patients could benefit from IVIg therapy and what dose of the preparation should be administrated. The ground-breaking question is: do the host genetic profiles influence the responsiveness and side-effects of IVIg therapy in TEN patients? Based on recent pharmacological, immunological and genetic findings, we suggest that the variability of IVIg therapy outcomes in TEN patients may be related to functional variants inFas,FasLand Fc-gamma receptor genes. This novel concept could lead to improved quality of care for patients with TEN, facilitating personalized therapy to reduce mortality.

Návaznosti

ROZV/28/LF5/2020, interní kód MU

Název: Molekulárně genetické a mikrobiologické analýzy u pacientů s termálně a netermálně indukovanou ztrátou kožního krytu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulárně genetické a mikrobiologické analýzy u pacientů s termálně a netermálně indukovanou ztrátou kožního krytu, Interní rozvojové projekty

Citovat

BOŘILOVÁ LINHARTOVÁ, Petra, Daniela GACHOVÁ a Břetislav LIPOVÝ. Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept. JOURNAL OF DERMATOLOGY. HOBOKEN: WILEY, 2020, roč. 47, č. 11, s. 1236-1248. ISSN 0385-2407. Dostupné z: https://dx.doi.org/10.1111/1346-8138.15583.

@article{1683660,
   author = {Bořilová Linhartová, Petra and Gachová, Daniela and Lipový, Břetislav},
   article_location = {HOBOKEN},
   article_number = {11},
   doi = {http://dx.doi.org/10.1111/1346-8138.15583},
   keywords = {Fas receptor; gene variability; i; v; immunoglobulin therapy; pharmaco-immunogenetics; toxic epidermal necrolysis},
   language = {eng},
   issn = {0385-2407},
   journal = {JOURNAL OF DERMATOLOGY},
   title = {Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15583},
   volume = {47},
   year = {2020}
}

TY  - JOUR
ID  - 1683660
AU  - Bořilová Linhartová, Petra - Gachová, Daniela - Lipový, Břetislav
PY  - 2020
TI  - Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept
JF  - JOURNAL OF DERMATOLOGY
VL  - 47
IS  - 11
SP  - 1236-1248
EP  - 1236-1248
PB  - WILEY
SN  - 03852407
KW  - Fas receptor
KW  - gene variability
KW  - i
KW  - v
KW  - immunoglobulin therapy
KW  - pharmaco-immunogenetics
KW  - toxic epidermal necrolysis
UR  - https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15583
L2  - https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15583
N2  - Toxic epidermal necrolysis (TEN) represents a rare drug-induced autoimmune reaction with delayed-type hypersensitivity that initiates the process of developing massive keratinocyte apoptosis, dominantly in the dermoepidermal junction. Although the etiopathophysiology has not yet been fully elucidated, the binding of Fas ligand (FasL, CD95L) to the Fas receptor (CD95) was shown to play a key role in the induction of apoptosis in this syndrome. The knowledge of the role of immunoglobulin G (IgG) in inhibition of Fas-mediated apoptosis contributed to the introduction of i.v. Ig (IVIg) in the therapy of TEN patients. Despite great enthusiasm for this therapy at the end of the 1990s, subsequent studies in various populations and meta-analyses could not unequivocally confirm the efficacy of the IVIg-based treatment concept. Today, therefore, we are faced with the dilemmas of how to adjust therapy of TEN patients most effectively, which patients could benefit from IVIg therapy and what dose of the preparation should be administrated. The ground-breaking question is: do the host genetic profiles influence the responsiveness and side-effects of IVIg therapy in TEN patients? Based on recent pharmacological, immunological and genetic findings, we suggest that the variability of IVIg therapy outcomes in TEN patients may be related to functional variants inFas,FasLand Fc-gamma receptor genes. This novel concept could lead to improved quality of care for patients with TEN, facilitating personalized therapy to reduce mortality.
ER  -

BOŘILOVÁ LINHARTOVÁ, Petra, Daniela GACHOVÁ a Břetislav LIPOVÝ. Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept. \textit{JOURNAL OF DERMATOLOGY}. HOBOKEN: WILEY, 2020, roč.~47, č.~11, s.~1236-1248. ISSN~0385-2407. Dostupné z: https://dx.doi.org/10.1111/1346-8138.15583.

Podrobný výpis o publikaci